MabGenesis

Yokohama, Japan · Founded 2019 · Privately Held (backing)

Operator of a biopharmaceutical company intended to develop therapeutic monoclonal antibody drugs for humans and animals. MabGenesis is based in Yokohama, Japan and was founded in 2019. Its last reported valuation was $18.6 million in Dec 2024. It has raised $8.8 million.

Last reported valuation
$18.6M
Oct 2026
Priced at
—
Total raised
$8.8M
Last round
—

Who backs MabGenesis?

9 investors
InvestorType
SMBC Venture CapitalVenture capital
Beyond Next VenturesVenture capital
Regional Economy Vitalization Corporation of JapanOther
REVIC CapitalOther
Anniversaire Holdings—
Axil Capital Partners—
Long Black Partners—
Miyagin Venture Capital—
Miyazaki Taiyo Capital—
The directory is free. Investor activity — the working column — is Pro.Unlock prospecting columns

Membership and data by Private Market View

MabGenesis investors

Free account
More of MabGenesis with a free account
  • ·Watch MabGenesis: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

For fundraisers
Work this list, don’t just read it

These 9 firms already write checks for companies like MabGenesis. Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.

Find investors like these →

Membership and data by Private Market View